Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
58 results about "C-Met inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
C-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF). These inhibitors may have therapeutic application in the treatment of various types of cancers.
Inhibitors of c-met and uses thereof
The present invention relates to compounds and methods use as inhibitors of c-Met. Certain compounds of the subject invention have the following structural formula (I). Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
Owner:CEPHALON INC
Pyridopyrazines and derivatives thereof as alk and c-Met inhibitors
Owner:CEPHALON INC
Pyridino five-membered heterocyclic derivative as well as preparation method and applications thereof
InactiveCN102827186ANovel structureGood c-Met inhibitory activity in vitroOrganic active ingredientsOrganic chemistryPyridineC-Met inhibitor
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Method of administration and treatment
InactiveUS20140221372A1Short time to progressionOrganic active ingredientsMicrobiological testing/measurementMedicineHaplotype
The present invention is directed to methods of administering foretinib or pharmaceutically acceptable salts or solvates thereof a c-Met inhibitor to a patient in need thereof comprising:determining whether said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and / or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene; andif said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and / or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a pharmaceutical composition comprising foretinib or a pharmaceutically acceptable salt thereof.
Owner:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 2) LTD +1
Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
![Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/452fe59b-67a5-4b95-af97-1745476293c4/US08487096-20130716-C00001.png "Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors")
![Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/452fe59b-67a5-4b95-af97-1745476293c4/US08487096-20130716-C00002.png "Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors")
![Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/452fe59b-67a5-4b95-af97-1745476293c4/US08487096-20130716-C00003.png "Imidazo[1,2-B][1,2,4]triazines as C-MET inhibitors")
Owner:INCYTE HLDG CORP
Heterocyclic pyridone compound, and intermediate, preparation method and use thereof
ActiveUS9562060B2Organic active ingredientsOrganic chemistryChemical compoundTyrosine-kinase inhibitor
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD
Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
![Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/32483d87-5d87-4cb1-94fc-529336e209eb/US20110212967A1-20110901-C00001.png "Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors")
![Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/32483d87-5d87-4cb1-94fc-529336e209eb/US20110212967A1-20110901-C00002.png "Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors")
![Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/32483d87-5d87-4cb1-94fc-529336e209eb/US20110212967A1-20110901-C00003.png "Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors")
Owner:INCYTE HLDG CORP
Combination therapy using p53 activator and c-met inhibitor
ActiveUS20140212414A1Organic active ingredientsPeptide/protein ingredientsCombination therapyCancer research
A method of preventing and / or treating a cancer comprising co-administering a p53 activator and a c-Met inhibitor to a patient in need thereof.
Owner:SAMSUNG ELECTRONICS CO LTD
Combination therapy using c-met inhibitor and beta-catenin inhibitor
ActiveUS20150071930A1Good curative effectOrganic active ingredientsBiocideBeta-cateninCombination therapy
A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.
Owner:SAMSUNG ELECTRONICS CO LTD
Dosing of cabozantinib formulations
ActiveUS10159666B2Desired pharmacokineticDesired pharmacodynamic effectDigestive systemSkeletal disorderMetaboliteDepressant
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
Owner:EXELIXIS INC
(1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds, as well as preparation method and use thereof
The invention relates to (1,2,4)-triazolo-(4,3-b) (1,2,4)-triazine compounds which are of a novel structure and are shown in a formula (I) or formula (II), and a pharmaceutical salt, a prodrug, a hydrate or a solvate thereof, a preparation method of the compounds, a pharmaceutical composition containing the treatment effective dose of the compound and an application of the compound as a protein tyrosine kinase inhibitor, especially as a c-Met inhibitor, in the preparation of medicaments for preventing and / or treating c-Met abnormality-related diseases.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Dosing of Cabozantinib Formulations
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
Owner:EXELIXIS INC
Novel fused pyridine derivatives useful as c-Met tyrosine kinase inhibitors
ActiveCN104507930AOrganic active ingredientsOrganic chemistryTyrosine-kinase inhibitorMET Receptor Tyrosine Kinase
This invention relates to novel fused quinazoline derivatives of Formula I as c-Met inhibitors, their synthesis and uses for treating c-Met mediated disorders.
Owner:BETTA PHARM CO LTD
Pyrazolo[1,5-a]miazine compound and its preparation method and medical use
ActiveCN104250252AStrong antiproliferative activityEnhanced inhibitory effectOrganic active ingredientsOrganic chemistryDiseaseReceptor tyrosine kinase inhibitor
The invention relates to a pyrazolo[1,5-a]miazine compound and its preparation method and medical use. The invention relates to the preparation method of the pyrazolo[1,5-a]miazine compound shown in the general formula (I) and its salt, a pharmaceutical composition containing the pyrazolo[1,5-a]miazine compound or its medicinal salt, the use of the pyrazolo[1,5-a]miazine compound or the pharmaceutical composition in the medicine field and especially as a receptor tyrosine kinase inhibitor and a c-Met inhibitor, and the use of the pyrazolo[1,5-a]miazine compound or the pharmaceutical composition in preparation of drugs for preventing and / or treating c-Met abnormality-related diseases.
![Pyrazolo[1,5-a]miazine compound and its preparation method and medical use](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/87c565b9-7348-4f70-958b-669bd83453f2/BDA00003428167000031.PNG "Pyrazolo[1,5-a]miazine compound and its preparation method and medical use")
![Pyrazolo[1,5-a]miazine compound and its preparation method and medical use](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/87c565b9-7348-4f70-958b-669bd83453f2/BDA00003428167000061.PNG "Pyrazolo[1,5-a]miazine compound and its preparation method and medical use")
![Pyrazolo[1,5-a]miazine compound and its preparation method and medical use](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/87c565b9-7348-4f70-958b-669bd83453f2/BDA00003428167000062.PNG "Pyrazolo[1,5-a]miazine compound and its preparation method and medical use")
Owner:SHANGHAI HANSOH BIOMEDICAL +1
Highly selective c-met inhibitors as anticancer agents
Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.
Owner:APOLLOMICS INC
Method for Determining Treatment Efficacy
The present invention provides a method for determining the efficacy of a c-Met inhibitor in treating a cell proliferative disorder, comprising: a) administering to a subject in need thereof a therapeutically effective amount of the c-Met inhibitor, or a pharmaceutically acceptable salt, prodrug or metabolite thereof, either alone or in combination with a therapeutically effective amount of a second anti-proliferative agent; and b) measuring the concentration of hepatocyte growth factor (HGF) in the serum from the subject, wherein if the concentration of serum HGF does not decrease, or if the concentration of serum HGF increases, the c-Met inhibitor is efficacious in treating the cell proliferative disorder.
Owner:ARQULE INC
Pyridazinone compounds, preparation method thereof, medicinal composition and application thereof
ActiveCN103664895AGood water solubilityHigh activitySenses disorderOrganic chemistryEster prodrugChemical compound
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to pyridazinone compounds as shown in general formula I or isomers thereof or pharmaceutically acceptable salt, ester prodrug or solvate thereof, a preparation method thereof, a medicinal composition and application thereof in preparation of a tyrosine kinase inhibitor (especially c-Met inhibitor). The compounds or the medicinal composition thereof serving as a tyrosine kinase inhibitor (especially c-Met inhibitor) can be used for preventing and / or treating neoplastic diseases related to c-Met abnormality.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Biomarker hsp90 for predicting effect of a c-met inhibitor
ActiveUS20160030559A1Effect is exertedOrganic active ingredientsMicrobiological testing/measurementHSP90 Heat-Shock ProteinsCancer research
Owner:SAMSUNG ELECTRONICS CO LTD
Combination therapy using c-met inhibitor and c-myc inhibitor
ActiveUS20150071932A1Organic active ingredientsGenetic material ingredientsDepressantBULK ACTIVE INGREDIENT
A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a c-Myc Inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a c-Myc inhibitor, and a kit comprising a pharmaceutically effective amount of a c-Met inhibitor as an active ingredient, and a second pharmaceutical composition comprising a pharmaceutically effective amount of a c-Myc inhibitor as an active ingredient, packaged together.
Owner:SAMSUNG ELECTRONICS CO LTD
Method for treating cancer by combined application of c-MET inhibitor and sodium butyrate
InactiveCN103800905AGrowth inhibitionInhibition of transplantation efficiencyGenetic material ingredientsAnhydride/acid/halide active ingredientsCancer cellOncology
The invention relates to the technical field of cancer treatment methods, and in particular relates to a method for treating cancer by the combined application of a c-MET inhibitor and sodium butyrate. The method comprises the step of administrating a drug to a cancer patient through a sodium butyrate preparation and the c-MET inhibitor simultaneously. According to the method for treating the cancer by the combined application of the c-MET inhibitor and sodium butyrate, the growth of a tumor can be effectively inhibited, and the number of tumor stem cells is effectively decreased; moreover, the transplantation efficiency of cancer cells is effectively inhibited, the recurrence rate of the cancer is greatly reduced, and the method is easy to use and popularize.
Owner:JIANGSU LIFECEL TECH
Combination therapy using c-Met inhibitor and beta-catenin inhibitor
A method of preventing and / or treating a cancer including co-administering a c-Met inhibitor and a beta-catenin inhibitor to a subject in need thereof, a pharmaceutical composition comprising a c-Met inhibitor and a beta-catenin inhibitor, and a kit comprising a pharmaceutical composition comprising a c-Met inhibitor, and a pharmaceutical composition comprising a beta-catenin inhibitor packaged together.
Owner:SAMSUNG ELECTRONICS CO LTD
Quinoline compound and preparation method thereof, medicament combination containing compound and application of compound
The invention relates to a quinoline compound which is used as a c-Met depressant and is expressed by the general formula (I) below, a pharmaceutically acceptable salt or pharmaceutically acceptable solvate and a preparation method of the compound, a medicament combination containing the compound and application of the compounds in the preparation of medicaments for preventing or treating diseases relevant to abnormal cell proliferation, morphological change and hyperkinesia with respect to hepatocyte growth factor receptors (HGFR) in an organism as well as diseases relevant to angiogenesis or cancerometastasis, especially medicaments for treating or preventing growth and metastasis of tumors.
Owner:SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof
ActiveUS20160122339A1Easy to managePromote absorptionBiocideOrganic chemistryPyridineC-Met inhibitor
Provided are [1,2,4]triazol[4,3-a]pyridine derivatives as shown in the general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, wherein the pharmaceutical composition is used as a therapeutic agent, and especially used as a c-Met inhibitor and an immunosuppressant. Each substituent in the general formula (I) is the same as that defined in the specification.
![[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/287c37e8-c5a9-40f0-b78d-d3d13ae5e903/US20160122339A1-20160505-C00001.PNG "[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof")
![[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/287c37e8-c5a9-40f0-b78d-d3d13ae5e903/US20160122339A1-20160505-C00002.PNG "[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof")
![[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/287c37e8-c5a9-40f0-b78d-d3d13ae5e903/US20160122339A1-20160505-C00003.PNG "[1,2,4] triazol [4,3-a] pyridine derivative, preparation method therefor or medical application thereof")
Owner:JIANGSU HANSOH PHARMA CO LTD
4-phenoxyquinoline and alpha-acyloxyamide compound and preparation method and application thereof
ActiveCN110283165ANovel structureThe synthesis process is simpleOrganic chemistryAntineoplastic agentsStereochemistryC-Met inhibitor
The invention relates to a 4-phenoxyquinoline and alpha-acyloxyamide compound I. The 4-phenoxyquinoline and alpha-acyloxyamide compound I is taken as a protein tyrosine kinase (PTK) inhibitor, particularly a c-Met inhibitor. The invention also relates to a preparation method of the compound; the invention further relates to application of the 4-phenoxyquinoline and alpha-acyloxyamide compound I as a drug to the treatment of PTK c-Met related diseases, particularly c-Met related cancer.
Owner:威海惠安康生物科技有限公司
[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof
ActiveUS9512121B2Promote absorptionBig advantageOrganic active ingredientsOrganic chemistryPyridineStereochemistry
Provided are [1,2,4]triazol[4,3-a]pyridine derivatives as shown in the general formula (I), a preparation method therefor, and a pharmaceutical composition containing the derivative, wherein the pharmaceutical composition is used as a therapeutic agent, and especially used as a c-Met inhibitor and an immunosuppressant. Each substituent in the general formula (I) is the same as that defined in the specification.
![[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b1aa9ce-1501-4c8e-9bae-a8877ffd252e/US09512121-20161206-C00001.png "[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof")
![[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b1aa9ce-1501-4c8e-9bae-a8877ffd252e/US09512121-20161206-C00002.png "[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof")
![[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/5b1aa9ce-1501-4c8e-9bae-a8877ffd252e/US09512121-20161206-C00003.png "[1,2,4] triazol [4,3-A] pyridine derivative, preparation method therefor or medical application thereof")
Owner:JIANGSU HANSOH PHARMA CO LTD
Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition
InactiveUS20170224815A1Preventing and treating retinal microvasculature inflammationOrganic active ingredientsPeptide/protein ingredientsVascular inflammationBlood vessel
The present invention provides methods for preventing retinal microvasculature inflammation in patients with diabetes who are highly susceptible to developing diabetic retinopathy and / or diabetic macular edema. The methods comprise inhibiting C-met signaling pathway by administering a C-met inhibitor alone or in combination with anti-VEGF or steroid medications to diabetic patients. The methods thus provide a surprisingly effective prophylaxis and / or treatment for diabetic retinopathy and / or diabetic macular edema.
Owner:TIRGAN NIMA
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
InactiveCN108697794APharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsReceptor tyrosine kinase inhibitorTyrosine-kinase inhibitor
The present invention relates to a pharmaceutical combination which comprises (a) at least one antibody molecule (e.g., humanized antibody molecules) that bind to Programmed Death 1 (PD-1), and (b) atleast one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease; a pharmaceutical composition comprising such combination; a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of proliferative disease; and a commercial package comprising such combination.
Owner:NOVARTIS AG
Combination therapy using c-met inhibitor and igf-1r inhibitor
ActiveUS20160144027A1Organic active ingredientsAntibody mimetics/scaffoldsDual inhibitorMET Receptor Tyrosine Kinase
A method of preventing and / or treating a cancer, the method including co-administering a dual inhibitor of c-Met (hereinafter, ‘c-Met inhibitor’) and an IGF-1R inhibitor to a subject in need thereof and a use of IGF-1R as a marker for resistance to a c-Met inhibitor.
Owner:SAMSUNG ELECTRONICS CO LTD +1
Biomarker tff1 for predicting effect of c-met inhibitor
ActiveUS20150212077A1Guaranteed predictive effectCompound screeningApoptosis detectionCancer researchC-Met inhibitor
A method of predicting an effect of a c-Met inhibitor and / or selecting a subject for application of a c-Met inhibitor using TFF1, a method of monitoring an effect of a c-Met inhibitor using TFF1, and a method of treating and / or preventing cancer including administering a c-Met inhibitor to the selected subject.
Owner:SAMSUNG ELECTRONICS CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com